Eye Care

Pharmacists should learn the basics of this leading cause of vision loss among adults worldwide.

The approval marks the first and only FDA-approved treatment for dry eye disease that directly targets tear evaporation.

Data from the aflibercept 8 mg clinical trial program will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting, April 23 to 27.

Eye drops come in many forms and for many indications, such as redness, itchiness, dryness, allergies, dilating drops, glaucoma drops, lubricants, numbing agents, antibiotics, and to lower pressure.

Aflibercept injection (8 mg) in a 12-week dosing regimen was found non inferior in vision gains compared to 8-week dosing regimen with 2 mg.

The approval marks the first and only treatment for geographic atrophy, a leading cause of blindness.

Aflibercept injection is also indicted for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

Bausch + Lomb Corporation and Modulight anticipate that ML6710i will be available for eye care professionals during the first half of 2023.

Products range from natural eye relief to sleep aid.

Retinal vein occlusion is the second most common cause of vision loss from retinal vascular diseases.

Teprotumumab is the first fully human IgG1 monoclonal antibody approved by the FDA for the treatment of thyroid eye disease at its source not just reducing the symptoms.

Monkeypox may be transmitted through conjunctivitis, according to a new study.

Aflibercept 8 mg demonstrated non-inferiority in vision gains in both the 12- and 16-week dosing regimens.

Iheezo is a sterile, single use ophthalmic gel preparation.

Omidenepag isopropyl ophthalmic solution (Omlonti) eye drops are indicated to reduce elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.

Researchers will submit a new drug application to the FDA after a phase 3 trial found that iDose TR slow- and fast-release models met their primary endpoint in patients with glaucoma.

Pharmacists should ascertain whether self-treatment is appropriate and suggest medical care if it isn’t.

Study suggests gene therapy may effectively treat young children who were born colorblind via pathways connecting the brain and the retina.

Latanoprost (Xalatan) Sterile Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Study is the first to use an artificial intelligence algorithm to break down visual field loss in new-onset glaucoma cases among population groups in the United States.

Brinzolamide/brimonidine tartrate (Simbrinza) is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Ranibizumab-eqrn is the only biosimilar approved for all 5 Lucentis indications.

Thera Tears helps with the symptoms of dry eyes.

Findings suggest potential screening and disease detection opportunities.

Treatment with faricimab-svoa (Vabysmo) may improve vision with fewer injections and treatment sessions for patients with wet age-related macular degeneration compared to other treatments.

If approved, the 16-week dosing regimen could offer certain individuals a potentially longer treatment interval and physicians with greater flexibility to individualize treatment.

Olopatadine stabilizes ocular mast cells to prevent histamine release by allergens.

Acuvail ophthalmic solution is a nonsteroidal, anti-inflammatory indicated for the treatment of pain and inflammation following cataract surgery.

In clinical trials, Xiidra was found to improve eye dryness scores significantly compared with placebo.

Pilocarpine (Vuity) is a cholinergic muscarinic receptor agonist indicated for the treatment of presbyopia in adults.